Shares of WW International (WW, Financial) surged by 6% in pre-market trading, reaching $1.76. This increase follows news that the U.S. Food and Drug Administration (FDA) may revisit its decision to ban compounded versions of liraglutide, a drug used for weight loss.
WW International recently announced the integration of compounded semaglutide into its weight management program, with pricing starting at $129. This strategic move comes as the company seeks to enhance its product offerings in the competitive weight loss market.